HS-131, a near-infrared dye-conjugated Hsp90 inhibitor, effectively identifies oncogene-driven breast cancers across various molecular subtypes.

Immunofluorescence[1] was conducted on a tumor cell line using a concentration of 10 μM, with an incubation time of 30 minutes. The outcome was that various tissues and organs, such as the eyes, brain, heart, lung, liver, spleen, kidney, gut, urinary bladder, and skin, were effectively imaged ex vivo utilizing the IVIS imager machine. This imaging tool is designed to detect infrared (IR) wavelengths at 640 nm.

HS131 (10 nmol/mouse) effectively labeled human breast cancer xenografts of various molecular subtypes in SCID-beige mice, including luminal types (MCF-7, T-47D), HER2+ subtypes (BT474M1, KPL-4), and triple negative subtypes (MDA-MB-231, MDA-MB-468), chosen for their tumorigenic potential. Injected intravenously at a dosage of 10 nmol/mouse, HS131 demonstrated superior near-infrared (nIR) signal strength in all cancer subtypes when compared to HS152, with signal retention observable up to 24 hours post-injection.